semaglutide cardiac benefits Shows Secondary Cardiovascular Prevention in Patients Without Diabetes STEER_SCORE trial for the use

Use of empagliflozin in people with nephrolithiasis/recurrent renal calculi was previously not recommended in the NZSSD guidance

PALFORZIA is approved for children and adolescents aged 13 and 417 years, while XOLAIR can be used in individuals aged 1 year and older

This pricing model removes the financial barrier many patients face when accessing GLP-1 therapy

Combination of PIO with TOFO also suppressed oxidative stress (urinary 8-hydroxydeoxyguanosine) and cytokeratin-18 fragments (molecules that are essentially involved in the pathogenesis of NASH) vs

STEP-1 took 1961 adults with a BMI 30 (or 27 in people with 1 weight-related coexisting condition) without T2D and demonstrated mean weight reduction of 14.8% in participants taking semaglutide 2.4 mg weekly (vs

Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial